By Deena Beasley
LOS ANGELES (Reuters) – Express Scripts Holding Co (O:ESRX), one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly (N:LLY) and Amgen Inc (O:AMGN), but is excluding a rival medication made by Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA) after price negotiations with all three manufacturers. The decision represents a setback for Teva, which is in the midst of a corporate restructuring and had hoped to capture a sizable stake of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use to the patients it says are most likely to benefit from the new Amgen and Lilly migraine drugs.
